Celldex Therapeutics Inc. (CLDX)
$39.24
$-0.39
(-0.98%)
As on 01-Sep-2026 16:00EDT
Market cap
$3,072 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
4.4
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.4 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-17.3
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-4.4
-
Face value
--
-
Shares outstanding
78,529,532
10 Years Aggregate
CFO
$-847.38 Mln
EBITDA
$-890.09 Mln
Net Profit
$-1,062.90 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Celldex Therapeutics (CLDX)
| 44.5 | 3.1 | 24.8 | 77.7 | 12.0 | -5.7 | -2.4 |
|
BSE Sensex*
| -9.6 | -2.0 | 3.0 | -4.8 | 5.4 | 5.9 | 10.4 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Celldex Therapeutics (CLDX)
| 7.5 | -36.0 | -11.0 | 15.3 | 120.5 | 685.7 | -24.9 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Celldex Therapeutics (CLDX)
|
39.2 | 3,072.1 | 0.1 | -300.6 | -268,385.7 | -48.4 | -- | 4.4 |
| 82.7 | 11,993.9 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.9 | |
| 260.3 | 16,261.1 | 1,054.4 | 755.9 | 5.7 | -- | 19 | 9.8 | |
| 71.4 | 10,022.2 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.3 | |
| 56.9 | 13,491.7 | 2,435.9 | 860.6 | 31.0 | 43 | 17.4 | 7.4 | |
| 107.7 | 11,957.0 | 1,663.7 | 413.6 | 36.3 | 430 | 30.9 | 84.5 | |
| 363.8 | 10,402.8 | 440.5 | 241.5 | 33.4 | 18.7 | 44.1 | 7.8 | |
| 538.7 | 12,332.1 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 24.0 | |
| 583.2 | 16,765.1 | 2,782.3 | 491.5 | 21.1 | 110.1 | 35.2 | 39.3 | |
| 353.4 | 9,625.4 | 0.0 | -339.1 | -- | -30.6 | -- | 7.6 |
Shareholding Pattern
View DetailsAbout Celldex Therapeutics (CLDX)
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific... antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. It develops clinical programs, including Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis; and CDX-622, a bispecific candidate for inflammatory diseases, which targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin and depleting mast cells through stem cell factor starvation. Celldex Therapeutics, Inc. is headquartered in Hampton, New Jersey. Read more
-
Founder, President, CEO & Director
Mr. Anthony S. Marucci M.B.A.
-
Founder, President, CEO & Director
Mr. Anthony S. Marucci M.B.A.
-
Headquarters
Hampton, NJ
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Celldex Therapeutics (CLDX)
What is the current share price of Celldex Therapeutics Inc (CLDX) Today?
The share price of Celldex Therapeutics Inc (CLDX) is $39.24 (NASDAQ) as of 01-Sep-2026 16:00 EDT. Celldex Therapeutics Inc (CLDX) has given a return of 12.04% in the last 3 years.
What is the current PB & PE ratio of Celldex Therapeutics Inc (CLDX)?
Since, TTM earnings of Celldex Therapeutics Inc (CLDX) is negative, P/E ratio is not available.
The P/B ratio of Celldex Therapeutics Inc (CLDX) is 4.45 times as on 28-Aug-2026, a 14 discount to its peers’ median range of 5.18 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-6.98 |
3.43 |
2024 |
-10.62 |
2.24 |
2023 |
-14.59 |
4.81 |
2022 |
-18.70 |
6.44 |
2021 |
-25.59 |
4.30 |
What is the 52 Week High and Low of Celldex Therapeutics Inc (CLDX)?
The 52-week high and low of Celldex Therapeutics Inc (CLDX) are Rs 45.14 and Rs 21.77 as of 02-Sep-2026.
What is the market cap of Celldex Therapeutics Inc (CLDX)?
Celldex Therapeutics Inc (CLDX) has a market capitalisation of $ 3,072 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Celldex Therapeutics Inc (CLDX)?
Before investing in Celldex Therapeutics Inc (CLDX), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.